The flu vaccine engineered for 2022-’23’s atypical early season reduced the risk of “medically attended influenza A(H3N2) illness” by half, according to a study published Feb. 2 in Eurosurveillance.
Read the full post on Becker's Hospital Review - Healthcare News
